JP2009138003A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009138003A5 JP2009138003A5 JP2009022892A JP2009022892A JP2009138003A5 JP 2009138003 A5 JP2009138003 A5 JP 2009138003A5 JP 2009022892 A JP2009022892 A JP 2009022892A JP 2009022892 A JP2009022892 A JP 2009022892A JP 2009138003 A5 JP2009138003 A5 JP 2009138003A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- drug
- administered
- taurolidine
- dosing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28074801P | 2001-04-03 | 2001-04-03 | |
| US60/280748 | 2001-04-03 | ||
| US28171301P | 2001-04-06 | 2001-04-06 | |
| US28171001P | 2001-04-06 | 2001-04-06 | |
| US28171201P | 2001-04-06 | 2001-04-06 | |
| US28171101P | 2001-04-06 | 2001-04-06 | |
| US60/281710 | 2001-04-06 | ||
| US60/281712 | 2001-04-06 | ||
| US60/281711 | 2001-04-06 | ||
| US60/281713 | 2001-04-06 | ||
| US28493301P | 2001-04-20 | 2001-04-20 | |
| US28493401P | 2001-04-20 | 2001-04-20 | |
| US60/284934 | 2001-04-20 | ||
| US60/284933 | 2001-04-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002100404A Division JP2002363102A (ja) | 2001-04-03 | 2002-04-02 | 新形成細胞の細胞消滅死を誘導する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009138003A JP2009138003A (ja) | 2009-06-25 |
| JP2009138003A5 true JP2009138003A5 (2) | 2011-09-15 |
| JP5232678B2 JP5232678B2 (ja) | 2013-07-10 |
Family
ID=27569569
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002100404A Pending JP2002363102A (ja) | 2001-04-03 | 2002-04-02 | 新形成細胞の細胞消滅死を誘導する方法 |
| JP2009022892A Expired - Fee Related JP5232678B2 (ja) | 2001-04-03 | 2009-02-03 | 新形成細胞の細胞消滅死を誘導する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002100404A Pending JP2002363102A (ja) | 2001-04-03 | 2002-04-02 | 新形成細胞の細胞消滅死を誘導する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20030027818A1 (2) |
| EP (2) | EP1247524B1 (2) |
| JP (2) | JP2002363102A (2) |
| CA (2) | CA2379734C (2) |
| ES (2) | ES2562827T3 (2) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8304390B2 (en) * | 1997-07-31 | 2012-11-06 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method of treatment for preventing or reducing tumor growth in the liver of patient |
| US20070275955A1 (en) * | 1997-07-31 | 2007-11-29 | Ed. Geistlich Soehne Ag | Method of treating tumors |
| US20050124608A1 (en) * | 2001-04-03 | 2005-06-09 | Redmond H. P. | Treatment of cancers |
| US8030301B2 (en) * | 1999-06-04 | 2011-10-04 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of cancers with methylol-containing compounds and at least one electrolyte |
| US6821968B2 (en) * | 2001-09-26 | 2004-11-23 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Stable taurolidine electrolyte solutions |
| US7892530B2 (en) * | 1999-06-04 | 2011-02-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of tumor metastases and cancer |
| US7345039B2 (en) * | 1999-06-04 | 2008-03-18 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
| US20020177571A1 (en) * | 2000-11-29 | 2002-11-28 | Gordon Erlinda M. | Targeted vectors for cancer immunotherapy |
| US20030092707A1 (en) * | 2001-10-19 | 2003-05-15 | Redmond H. Paul | Treatment of breast cancer |
| US8052966B2 (en) * | 2003-04-21 | 2011-11-08 | University Of Southern California | Methods and compositions for treating metastatic cancer |
| US20070178066A1 (en) * | 2003-04-21 | 2007-08-02 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
| US20090123428A1 (en) * | 2003-04-21 | 2009-05-14 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
| CA2482687C (en) * | 2003-09-29 | 2012-11-20 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of mesothelioma |
| RU2433826C2 (ru) * | 2005-11-29 | 2011-11-20 | Новартис Аг | Композиции хинолинонов |
| ES2377206T3 (es) | 2006-01-06 | 2012-03-23 | Ed Geistlich Sohne Ag Fur Chemische Industrie | Composiciones irradiadas y tratamiento de cánceres con radiación en combinación con taurolidina y/o taurultam |
| WO2008029264A2 (en) * | 2006-09-07 | 2008-03-13 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method of treating bone cancer |
| CN103118669B (zh) * | 2010-06-01 | 2016-01-13 | 盖斯特里希医药公司 | 口服药物治疗方法和组合物 |
| WO2017040655A1 (en) * | 2015-08-31 | 2017-03-09 | Cormedix Inc. | Delivery of active agents using nanofiber webs |
| US20190381060A1 (en) | 2016-01-11 | 2019-12-19 | Cormedix Inc. | Taurolidine treatment for myc-expressing tumors in mammalian bodies |
| JP2021535163A (ja) * | 2018-08-28 | 2021-12-16 | コーメディクス・インコーポレーテッド | タウロリジン加水分解産物による神経芽細胞腫治療 |
| CN113226325A (zh) * | 2018-08-31 | 2021-08-06 | 科医公司 | 牛磺罗定对哺乳动物体内表达myc的肿瘤的治疗 |
| WO2020234829A1 (en) * | 2019-05-22 | 2020-11-26 | Geistlich Pharma Ag | Methods and compositions for inhibiting gapdh |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8617482D0 (en) | 1986-07-17 | 1986-08-28 | Geistlich Soehne Ag | Pharmaceutical composition |
| US5210083A (en) | 1986-07-17 | 1993-05-11 | Ed. Geistlich Sohne A.G. Fur Chemische Industrie | Pharmaceutical compositions |
| GB9005856D0 (en) * | 1990-03-15 | 1990-05-09 | Geistlich Soehne Ag | Compositions |
| GB9015108D0 (en) * | 1990-07-09 | 1990-08-29 | Geistlich Soehne Ag | Chemical compositions |
| AU641529B2 (en) * | 1990-07-30 | 1993-09-23 | Bloomfield D.A. | Zwitterionic compounds and their N-halo derivatives for use in the treatment of clinical conditions |
| GB9600426D0 (en) * | 1996-01-10 | 1996-03-13 | Ed Geistlich Sohne A G | Compositions |
| US5858990A (en) | 1997-03-04 | 1999-01-12 | St. Elizabeth's Medical Center | Fas ligand compositions for treatment of proliferative disorders |
| BR9809149A (pt) | 1997-05-20 | 2000-08-01 | Galenica Pharmaceuticals Inc | Análogos de triterpeno saponina dotados de adjuvante e atividade imonoestimulatória |
| CA2290537C (en) * | 1997-05-22 | 2007-10-02 | Oklahoma Medical Research Foundation | Use of taurolidine for treatment of leukemias |
| GB9716219D0 (en) * | 1997-07-31 | 1997-10-08 | Geistlich Soehne Ag | Prevention of metastases |
| US6479481B1 (en) | 1999-06-04 | 2002-11-12 | Ed. Geistlich Soehne Ag Fur Chemische Industrie | Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS) |
| JP5027369B2 (ja) | 1999-12-06 | 2012-09-19 | ガイストリッヒ ファーマ アーゲー | 腫瘍を治療する方法 |
| CA2363973C (en) * | 2000-11-28 | 2009-03-10 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
| UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
-
2002
- 2002-03-29 US US10/109,058 patent/US20030027818A1/en not_active Abandoned
- 2002-04-02 JP JP2002100404A patent/JP2002363102A/ja active Pending
- 2002-04-02 CA CA2379734A patent/CA2379734C/en not_active Expired - Lifetime
- 2002-04-02 CA CA2692295A patent/CA2692295C/en not_active Expired - Lifetime
- 2002-04-03 EP EP02252414.4A patent/EP1247524B1/en not_active Expired - Lifetime
- 2002-04-03 ES ES10009649.4T patent/ES2562827T3/es not_active Expired - Lifetime
- 2002-04-03 EP EP10009649.4A patent/EP2258373B1/en not_active Expired - Lifetime
- 2002-04-03 ES ES02252414.4T patent/ES2542842T3/es not_active Expired - Lifetime
-
2009
- 2009-02-03 JP JP2009022892A patent/JP5232678B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009138003A5 (2) | ||
| JP2002363102A5 (2) | ||
| JP2020033360A5 (2) | ||
| JP2011173928A5 (2) | ||
| JP2009102342A5 (2) | ||
| JP2015515475A5 (2) | ||
| JP2011068653A5 (2) | ||
| JP2015083580A5 (2) | ||
| ME02477B (me) | Genz 112638 za lečenje gošeove ili fabrijeve bolesti u kombinacionoj terapiji | |
| JP2016185995A5 (2) | ||
| JP2015524444A5 (2) | ||
| CA2379734A1 (en) | Treatment of cancers | |
| JP2008535785A5 (2) | ||
| JP2018509419A5 (2) | ||
| JP2005517040A5 (2) | ||
| JP2020510043A5 (2) | ||
| JP2019518022A5 (2) | ||
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| RU2007119067A (ru) | Средство для лечения синдрома раздраженного кишечника с преобладанием диареи | |
| RU2015113031A (ru) | Использование 3-n-бутил изоиндолин кетонов при приготовлении лекарственных средств для профилактики и лечения церебрального инфаркта | |
| RU2014125519A (ru) | Ацил-гидразоновые и оксадиазоловые соединения, фармацевтические композиции, содержащие их, и их применение | |
| WO2012075754A1 (zh) | 一种治疗急性淋巴白血病的复方药物组合物 | |
| RU2016110546A (ru) | Комбинированная лекарственная терапия | |
| Seymour | Drug interactions in dentistry | |
| JP2020512408A5 (2) |